Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.81 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336024 | 0.91 | ADORA2B (0.83) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL5334257 | 0.90 | ADORA2B (0.82) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL14517865 | 0.90 | ADORA2B (0.82) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL1780657 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL4759172 | 0.85 | ADORA2B (0.73) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL1569329 | 0.84 | ADORA2B (0.89) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780628 | 0.82 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267751 | 0.80 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1779738 | 0.79 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267752 | 0.78 | ADORA2B (0.64) | ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626494-A1 | LYOPHILIZED AND SPRAYABLE SILK FIBROIN AND MODIFIED SILK FIBROIN FORMS | Evolved by Nature, Inc. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4587635-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | Evolved by Nature, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2024059862-A9 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2024119107-A1 | LYOPHILIZED AND SPRAYABLE SILK FIBROIN AND MODIFIED SILK FIBROIN FORMS | EVOLVED BY NATURE, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024059862-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | claimed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | claimed |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-11-06 | — | — | US | claimed |
| EP-4703470-A1 | CELLULASE VARIANTS | AB Enzymes Finland Oy (FI) | 2026-03-04 | — | — | EP | disclosed |
| EP-4626494-A1 | LYOPHILIZED AND SPRAYABLE SILK FIBROIN AND MODIFIED SILK FIBROIN FORMS | Evolved by Nature, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250277211-A1 | LPA inhibitors and uses thereof | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4610356-A1 | RNA INHIBITOR FOR INHIBITING LPA GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| EP-4587635-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | Evolved by Nature, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 4/4885ADORA2A 2/4885 |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.